{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:11:35Z","timestamp":1783901495667,"version":"3.55.0"},"reference-count":20,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:00:00Z","timestamp":1602115200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_raon-2020-0056_s_001_w2aab3b7b3b1b6b1aab1c16b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Two prospective randomized studies analysing cutaneous melanoma (CM) patients with sentinel lymph node (SLN) metastases and rapid development of systemic adjuvant therapy have changed our approach to stage III CM treatment. The aim of this study was to compare results of retrospective survival analysis of stage III CM patients\u2019 treatment from Slovenian national CM register to leading international clinical guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2020-0056_s_002_w2aab3b7b3b1b6b1aab1c16b2Aa\">\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>Since 2000, all Slovenian CM patients with primary tumour \u2265 TIb are treated at the Institute of Oncology Ljubljana and data are prospectively collected into a national CM registry. A retrospective analysis of 2426 sentinel lymph node (SLN) biopsies and 789 lymphadenectomies performed until 2015 was conducted using Kaplan-Meier survival curves and log-rank tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2020-0056_s_003_w2aab3b7b3b1b6b1aab1c16b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Positive SLN was found in 519\/2426 (21.4%) of patients and completion dissection (CLND) was performed in 455 patients. The 5-year overall survival (OS) of CLND group was 58%\n                      <jats:italic>vs<\/jats:italic>\n                      . 47% of metachronous metastases group (MLNM) (p = 0.003). The 5-year OS of patients with lymph node (LN) metastases and unknown primary site (UPM) was 45%\n                      <jats:italic>vs<\/jats:italic>\n                      . 21% of patients with synchronous LN metastasis. Patients with SLN tumour burden &lt; 0.3 mm had 5-year OS similar to SLN negative patients (86%\n                      <jats:italic>vs<\/jats:italic>\n                      . 85%; p = 0.926). The 5-year OS of patients with burden &gt; 1.0 mm was similar to the MLNM group (49%\n                      <jats:italic>vs<\/jats:italic>\n                      . 47%; p = 0.280).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_raon-2020-0056_s_004_w2aab3b7b3b1b6b1aab1c16b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Stage III melanoma patients is a heterogeneous group with significant OS differences. CLND after positive SLNB might still remain a method of treatment for selected patients with stage III.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2020-0056","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T18:11:11Z","timestamp":1602699071000},"page":"50-56","source":"Crossref","is-referenced-by-count":1,"title":["Completely resected stage III melanoma controversy - 15 years of national tertiary centre experience"],"prefix":"10.2478","volume":"55","author":[{"given":"Barbara","family":"Peric","sequence":"first","affiliation":[{"name":"Department of Surgery, Institute of Oncology Ljubljana , Ljubljana , Slovenia"},{"name":"Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Milicevic","sequence":"additional","affiliation":[{"name":"Department of Surgery, Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andraz","family":"Perhavec","sequence":"additional","affiliation":[{"name":"Department of Surgery, Institute of Oncology Ljubljana , Ljubljana , Slovenia"},{"name":"Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Hocevar","sequence":"additional","affiliation":[{"name":"Department of Surgery, Institute of Oncology Ljubljana , Ljubljana , Slovenia"},{"name":"Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"},{"name":"Faculty of Medicine, University of Maribor , Maribor , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janez","family":"Zgajnar","sequence":"additional","affiliation":[{"name":"Department of Surgery, Institute of Oncology Ljubljana , Ljubljana , Slovenia"},{"name":"Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2020,10,8]]},"reference":[{"key":"2026071212043728875_j_raon-2020-0056_ref_001_w2aab3b7b3b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-34. doi: 10.1200\/JCO.2001.19.16.3622","DOI":"10.1200\/JCO.2001.19.16.3622"},{"key":"2026071212043728875_j_raon-2020-0056_ref_002_w2aab3b7b3b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 2014; 370: 599-609. doi: 10.1056\/NEJMoa1310460","DOI":"10.1056\/NEJMoa1310460"},{"key":"2026071212043728875_j_raon-2020-0056_ref_003_w2aab3b7b3b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Moody JA, Botham SJ, Dahill KE, Wallace DL, Hardwicke JT. Complications following completion lymphadenectomy versus therapeutic lymphadenectomy for melanoma - a systematic review of the literature. Eur J Surg Oncol 2017; 43:1760-7. doi: 10.1016\/j.ejso.2017.07.003","DOI":"10.1016\/j.ejso.2017.07.003"},{"key":"2026071212043728875_j_raon-2020-0056_ref_004_w2aab3b7b3b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"van Akkooi AC, de Wilt JH, Verhoef C, Schmitz PI, van Geel AN, Eggermont AM, et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol 2006; 17: 1578-85. doi: 10.1093\/annonc\/mdl176","DOI":"10.1093\/annonc\/mdl176"},{"key":"2026071212043728875_j_raon-2020-0056_ref_005_w2aab3b7b3b1b6b1ab2b1b5Aa","unstructured":"Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 2017; 376: 2211-22. doi: 10.1056\/ NEJMoa1613210"},{"key":"2026071212043728875_j_raon-2020-0056_ref_006_w2aab3b7b3b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Leiter U, Stadler R, Mauch C, Hohenberger W, Brockmeyer NH, Berking C, et al. Final analysis of DeCOG-SLT trial: No survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node. J Clin Oncol 2019; 37: 3000-8. doi: 10.1200\/JCO.18.02306","DOI":"10.1200\/JCO.18.02306"},{"key":"2026071212043728875_j_raon-2020-0056_ref_007_w2aab3b7b3b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. Eur J Cancer 2019; 119: 1-10. doi: 10.1016\/j. ejca.2019.07.001","DOI":"10.1016\/j.ejca.2019.07.001"},{"key":"2026071212043728875_j_raon-2020-0056_ref_008_w2aab3b7b3b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Long GV, Hauschild A, Santinami M, Atkinson V, Mandala M, Chiarion-Sileni V, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 2017; 377: 1813-23. doi: 10.1056\/NEJMoa1708539","DOI":"10.1056\/NEJMoa1708539"},{"key":"2026071212043728875_j_raon-2020-0056_ref_009_w2aab3b7b3b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017; 377: 1824-35. doi: 10.1056\/NEJMoa1709030","DOI":"10.1056\/NEJMoa1709030"},{"key":"2026071212043728875_j_raon-2020-0056_ref_010_w2aab3b7b3b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Franke V, van Akkooi ACJ. The extent of surgery for stage III melanoma: how much is appropriate? Lancet Oncol 2019; 20: e167-e174. doi: 10.1016\/ S1470-2045(19)30099-3","DOI":"10.1016\/S1470-2045(19)30099-3"},{"key":"2026071212043728875_j_raon-2020-0056_ref_011_w2aab3b7b3b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Bello DM, Faries MB. The landmark series: MSLT-1, MSLT-2 and DeCOG (management of lymph nodes). Ann Surg Oncol 2020; 27: 15-21. doi: 10.1245\/s10434-019-07830-w","DOI":"10.1245\/s10434-019-07830-w"},{"key":"2026071212043728875_j_raon-2020-0056_ref_012_w2aab3b7b3b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Gershenwald JE, Scolyer RA. Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond. Ann Surg Oncol 2018; 25: 210510. doi: 10.1245\/s10434-018-6513-7","DOI":"10.1245\/s10434-018-6513-7"},{"key":"2026071212043728875_j_raon-2020-0056_ref_013_w2aab3b7b3b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Blankenstein SA, van Akkooi ACJ. Adjuvant systemic therapy in high-risk melanoma. Melanoma Res 2019; 29: 358-64. doi: 10.1097\/ CMR.0000000000000604","DOI":"10.1097\/CMR.0000000000000604"},{"key":"2026071212043728875_j_raon-2020-0056_ref_014_w2aab3b7b3b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Madu MF, Wouters MW, van Akkooi AC. Sentinel node biopsy in melanoma: Current controversies addressed. Eur J Surg Oncol 2017; 43: 517-33. doi: 10.1016\/j.ejso.2016.08.007","DOI":"10.1016\/j.ejso.2016.08.007"},{"key":"2026071212043728875_j_raon-2020-0056_ref_015_w2aab3b7b3b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-9. doi: 10.1001\/archsurg.1992.01420040034005","DOI":"10.1001\/archsurg.1992.01420040034005"},{"key":"2026071212043728875_j_raon-2020-0056_ref_016_w2aab3b7b3b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Cook MG, Green MA, Anderson B, Eggermont AM, Ruiter DJ, Spatz A, et al. The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol 2003; 200: 314-9. doi: 10.1002\/path.1365","DOI":"10.1002\/path.1365"},{"key":"2026071212043728875_j_raon-2020-0056_ref_017_w2aab3b7b3b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Delgado AF, Delgado AF. Complete lymph node dissection in melanoma: A systematic review and meta-analysis. Anticancer Res 2017; 37: 6825-9. doi: 10.21873\/anticanres.12143","DOI":"10.21873\/anticanres.12143"},{"key":"2026071212043728875_j_raon-2020-0056_ref_018_w2aab3b7b3b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Ma Q, Dieterich LC, Detmar M. Multiple roles of lymphatic vessels in tumor progression. Curr Opin Immunol 2018; 53: 7-12. doi: 10.1016\/j. coi.2018.03.018","DOI":"10.1016\/j.coi.2018.03.018"},{"key":"2026071212043728875_j_raon-2020-0056_ref_019_w2aab3b7b3b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandala M, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma. J Clin Oncol 2018; 36: 3441-9. doi: 10.1200\/ JCO.18.01219","DOI":"10.1200\/JCO.18.01219"},{"key":"2026071212043728875_j_raon-2020-0056_ref_020_w2aab3b7b3b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Verver D, van KD, van Akkooi ACJ, Rutkowski P, Powell BWEM, Robert C, et al. Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations. Eur J Cancer 2018; 96: 25-33. doi: 10.1016\/j.ejca.2018.02.022","DOI":"10.1016\/j.ejca.2018.02.022"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/content.sciendo.com\/view\/journals\/raon\/ahead-of-print\/article-10.2478-raon-2020-0056\/article-10.2478-raon-2020-0056.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2020-0056","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T23:59:48Z","timestamp":1783900788000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2020-0056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,8]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,10,8]]},"published-print":{"date-parts":[[2020,10,8]]}},"alternative-id":["10.2478\/raon-2020-0056"],"URL":"https:\/\/doi.org\/10.2478\/raon-2020-0056","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,8]]}}}